trending Market Intelligence /marketintelligence/en/news-insights/trending/x5j_putncfedz_z9wa4vvq2 content esgSubNav
In This List

Moberg Pharma names replacement for retiring chief medical officer

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022

Blog

Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes

Blog

Investment Banking Essentials Newsletter April Edition - 2022


Moberg Pharma names replacement for retiring chief medical officer

Moberg Pharma AB's Kjell Rensfeldt will retire as vice president of research and development and chief medical officer.

The Sweden-based pharmaceutical company said Rensfeldt will continue to serve as a senior adviser on a part-time basis following his retirement "during the fall," according to an Aug. 13 release.

Shaw Sorooshian will replace Rensfeldt as Moberg Pharma's vice president and chief medical officer. Sorooshian is joining the company from Swedish Orphan Biovitrum AB, a global rare disease company, where he served as senior director of global medical affairs. Prior to Sobi, he held senior roles at Shire PLC, H. Lundbeck A/S and Organon Laboratories Ltd.